A Clinical Study on Anti-Hypertensive Effect and Safety of Candesartan Cilexetil (Atacand) in Mild to Moderate Hypertensive Patients

Seokmin KANG; Namsik CHUNG; Dong-Hoon CHOI; Shinki AHN; Sejoong RIM; Jon-Won HA; Yangsoo JANG; Won-Heum SHIM; Seung-Yeon CHO; Sung-Soon KIM; Sunho LEE

BACKGROUND AND

OBJECTIVES:

Candesartan cilexetil (Atacand ), a selective type I angiotensin II receptor blocker, has recently been introduced as a new antihypertensive agent. We evaluated its anti-hypertensive effect and safety in mild to moderate hypertensive patients. MATERIALS AND

METHODS:

Candesartan cilexetil, 8 mg or 16 mg, was administered once a day over 8 weeks period in the patients with mild to moderate hypertension (25 male, 26 female, mean age 53.5+/-1.2 years). For safety evaluation, laboratory tests were performed before and after treatment with candesartan cilexetil. Changes in blood pressure, heart rate and electrocardiogram were also observed.

RESULTS:

1) The mean blood pressures in the sitting position were systolic 164.1+/-2.1 mmHg and diastolic 106.3+/-0.8 mmHg before treatment, which were lowered to 135.4+/-2.0 mmHg and 89.1+/-1.1 mmHg, repectively after 8 weeks of treatment (p0.05). 4) Laboratory tests revealed no significant abnormality by the treatment with candesartan cilexetil. 5) Left ventricular hypertrophy by ECG criteria detected in 3 cases disappeared after treatment with candesartan cilexetil. 6) No significant side effects were observed during the treatment period.

CONCLUSION:

Candesartan cilexetil, 8 mg or 16 mg, once a day is an effective and well tolerated antihypertensive treatment. It has a significant dose-dependent antihypertensive effect.

Biblioteca Virtual en Salud

Hipertensión

Formato de exportación: